For anyone in Tifrā searching for CJC-1295, the foundational reality is that this compound moves through online research channels. What this means for Tifrā researchers is that geography is secondary to your ability to assess COA data — and those quality checks are accessible to anyone. The primary quality indicators for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. This guide gives Tifrā researchers the methodology to evaluate CJC-1295 vendors systematically and source high-purity CJC-1295 with confidence.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Tifrā researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Evaluating CJC-1295 vendors begins with the COA: request the batch-specific certificate before placing an order, not after. A COA for CJC-1295 should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all batch-matched. Community reputation in research forums is a valuable complement to COA verification — vendors with consistently positive reports over 12+ months have proved themselves through consistent results. For Tifrā researchers making a first CJC-1295 purchase: apply these quality criteria before ordering, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Tifrā
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and restricted human research data. Storage requirements for CJC-1295: lyophilised powder at minus 20°C, reconstituted solution refrigerated at 2-8°C and finished within 30 days of reconstitution; reconstitute only with bacteriostatic water. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger dangerous immune responses at minute levels, and no discount compensates for this missing data. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is not a licensed human medication and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
